Cut internal review cycles in pharma and medtech. Discover how submission-ready translation reduces MLR friction and launch delays.
In many pharmaceutical and medtech organizations, internal subject matter experts (SME) end up rewriting 30–40% of a translated document during the Medical, Legal, and Regulatory (MLR) review.
Industry benchmarks reflect this inefficiency. In the European market, average content approval timelines hover around 20 days, with the MLR process typically spanning 1.3 review cycles. At first glance, that may sound reasonable. But high-performing organizations have shown that timelines can be reduced by more than 35% while keeping review cycles close to one.
The difference is language that arrives closer to submission-ready form. Let’s find out more about the operational impact of getting translation right from the start.
Why Review Cycles Multiply in Regulated Environments
When review rounds increase, it’s rarely because of one catastrophic translation error. More often, it’s the accumulation of small misalignments that trigger large-scale rewriting.
-
Terminology misalignment from day one.
In regulated content, terminology is controlled. Often it has been negotiated in previous filings or aligned with specific health authority expectations.
If a translation starts without a validated, sponsor-approved glossary, linguists are forced to make informed guesses. They may select terms that are medically correct but misaligned with internal regulatory precedent.
For example, in French regulatory writing, “investigational medicinal product” is consistently rendered as médicament expérimental. Alternatives such as médicament à l’étude or traitement à l’étude may be understandable, but they are not the officially recognized phrasing.
When an SME encounters these “near misses,” every instance is corrected. One correction becomes twenty. And with each tracked change, the risk of secondary errors increases.
-
Disconnected knowledge systems.
In Life Science translation, every approved sentence should become an asset for future projects. Yet, many workflows still operate in silos.
If your language provider lacks access to:
-
- approved SmPC phrasing,
- established Patient Information Leaflet terminology, or
- historical labeling decisions,
they lack your “regulatory memory.” As a result, identical concepts are translated differently across documents in the same submission dossier.
Reviewers then spend valuable time re-litigating language that was already approved months—or years—ago.
-
Linguistically correct, but not regulator-ready.
Scientific writing often explains, explores, or contextualizes. Regulatory writing does not. It states, specifies, and adheres to established structural conventions.
For example, regulatory documents tend to rely on controlled modality: “is indicated for,” “must not be used,” “may result in.” Verb tenses are deliberate. The tone is neutral, authoritative, and free of interpretive nuance.
A translation can be technically accurate and still “read wrong” to a reviewer. If tense shifts occur or if phrasing feels narrative rather than declarative, SMEs instinctively reshape the text.
In a nutshell, the review becomes a rewrite.
-
Literal translation of a flawed source.
Another common friction point arises when the source document itself contains inconsistencies.
If a protocol alternates between “patient,” “subject,” and “participant,” a literal translation will reproduce that inconsistency. However, evolving regulatory guidance may favor one term over the others in a given jurisdiction.
Submission-ready translation requires more than mirroring the source. It requires harmonization. A regulatory-aware linguist flags inconsistencies and aligns terminology with current expectations before the document reaches internal review.
The Hidden Cost of Internal Fixing
Repeated review rounds are an operational bottleneck with significant implications.
-
The economic weight of delay.
In drug development, time is one of the most expensive variables. Analyses estimate that for a product with $1 billion in annual peak sales, advancing a regulatory submission by just one month can generate approximately $60 million in net present value.
Now consider how internal review cycles contribute to that delay. A week lost in terminology corrections. Another week in stylistic rewrites. Additional days reconciling conflicting tracked-change versions.
These delays in a reference market often ripple into secondary markets, creating a compounding financial impact.
-
Reviewer fatigue and cognitive load.
SMEs are not hired to edit prose. They are hired to ensure clinical integrity and patient safety.
When review becomes repetitive rewriting, mental fatigue increases. Research shows that this fatigue reduces detection accuracy and increases the likelihood of oversight.
If reviewers are busy correcting tone and terminology, they have less mental bandwidth for:
-
- Verifying dosing accuracy.
- Confirming cross-references.
- Identifying subtle compliance risks.
-
Version confusion and compliance exposure
Multiple uncontrolled review rounds create version drift. Edits made in Word documents with tracked changes may not propagate consistently across related files. As a result, final dossiers can contain subtle discrepancies.
In regulated environments, inconsistencies are not harmless. A mistranslated dosage or safety statement is not a stylistic flaw; it is a compliance risk with potential legal consequences.
What Actually Reduces Review Rounds
If “better translators” alone were the solution, the industry would have solved this problem years ago. Sustainable reduction in review cycles requires structural adjustments.
-
Move review upstream.
Pre-project terminology validation is one of the most powerful interventions available. Before translation begins, key stakeholders should approve critical terminology. High-risk terms are locked. Preferred phrasing is confirmed. Legacy filings are referenced.
This shifts the process from reactive correction to proactive alignment.
-
Partner with regulatory-trained linguists.
Linguists experienced in EMA, FDA, or MDR-driven documentation understand structural expectations and template language. They anticipate the compliance lens through which the document will be evaluated.
-
Formalize feedback loops.
Every correction should become institutional knowledge. When corrections are categorized (i.e., true error versus stylistic preference) and embedded into translation memory and glossaries, repetition decreases.
Each project refines the baseline for the next, eventually moving the organization toward a “Right-First-Time” model.
-
Calibrate reviewers.
Alignment is not only for linguists. Internal reviewers benefit from calibration as well.
Brief alignment sessions clarify expectations:
-
- What qualifies as a critical error?
- What falls under personal preference?
- What tone is non-negotiable?
When criteria are shared and explicit, subjective rewrites decrease.
Conclusion
When internal SMEs rewrite translated content, the organization absorbs an avoidable operational cost. So, if your reviewers are consistently rewriting rather than approving, it’s time to examine the process.
At Montero Language Service, we design localization workflows that prioritize submission-readiness from the outset. If reducing internal review friction is on your agenda this year, let’s explore how we can orchestrate a more efficient path to approval. Reach out to us today.
